{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-271108","form_type":"8-K","ticker":"TSHA","cik":"0001806310","company_name":"Taysha Gene Therapies, Inc.","filed_at":"2022-10-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.223317+00:00","generated_at":"2026-06-23T00:09:42.672515+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Taysha prices $28M public offering of 14M shares at $2.00 per share","bullets":["Offering of 14M shares at $2.00/share; net proceeds ~$25.6M (or ~$29.6M if over-allotment exercised).","Underwriter granted 30-day option to purchase up to 2.1M additional shares at $1.88/share.","Closing expected October 31, 2022; Goldman Sachs & Co. LLC is sole book-runner.","Proceeds will be used for general corporate purposes; dilution to existing shareholders."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-271108","json":"https://secwatch.observer/filing/0001193125-22-271108.json","markdown":"https://secwatch.observer/filing/0001193125-22-271108.md","text":"https://secwatch.observer/filing/0001193125-22-271108.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806310/000119312522271108/0001193125-22-271108-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806310/000119312522271108/d421669d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T00:09:42.672515+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2cc36b856438cc9daa095ad43b02908bfa88b009","claim":"Taysha Gene Therapies, Inc. entered into Underwriting Agreement with Goldman Sachs & Co. LLC (effective 2022-10-26).","evidence_excerpt":"On October 26, 2022, Taysha Gene Therapies, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Goldman Sachs & Co. LLC (the “ Underwriter ”), to issue and sell 14,000,000 shares of common stock of the Company, par value $0.00001 per share (“ Common Stock ”), in an underwritten public offering pursuant to effective registration statements on Form S-3 (File No. 333-260069) and a related prospectus and prospectus supplement, in each case filed with the Securities and Exchange Commission (the “ Offering ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1806310/000119312522271108/0001193125-22-271108-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Goldman Sachs & Co. LLC"},{"label":"Effective","value":"2022-10-26"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}